Tracon pharmaceuticals, inc. (TCON)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities
Net loss

-19,482

-22,674

-26,494

-30,380

-33,808

-34,959

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

0

-27,629

-

-31,741

-32,317

-26,941

-24,410

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation

1,295

1,624

1,950

2,309

2,557

2,667

2,840

2,963

3,094

3,194

3,142

2,884

3,032

3,083

3,081

3,214

2,698

2,088

0

0

0

Common stock issued for services

-

-

-

-

-

-

-

-

-

29

0

0

0

-

-

-

-

-

-

-

-

Depreciation and amortization

19

22

25

27

28

28

28

28

32

48

65

80

93

94

88

81

67

51

0

0

0

Noncash interest

219

234

245

249

254

272

296

320

339

354

386

431

481

522

497

456

426

417

0

0

0

Amortization of debt discount

76

81

85

86

88

94

103

112

117

117

109

104

101

100

96

89

89

97

0

0

0

Amortization of premium/discount on short-term investments

-

52

96

141

135

100

59

16

9

9

7

4

0

-3

0

0

0

-

-

-

-

Lease asset amortization and liability accretion, net

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of preferred stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

65

0

0

0

Deferred rent

-

-

-

-

-

11

16

53

83

60

39

-12

-57

-53

-38

-34

-8

-4

0

0

0

Deferred revenue

-

-

-

-

-

-3,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

0

-1,518

-

-2,572

-3,003

-3,709

-3,550

0

0

0

Changes in assets and liabilities:
Prepaid expenses and other assets

-310

-651

-51

-900

-283

-92

-173

680

176

356

120

-799

-222

42

-935

-2,755

-383

424

0

0

0

Accounts payable and accrued expenses

-4,181

-3,421

-3,197

-343

167

4,142

5,569

3,981

4,961

776

-116

-48

-2,955

-2,203

746

1,299

5,625

6,144

0

0

0

Accrued compensation and related expenses

-120

-109

-100

116

-1,019

-30

-169

-275

801

-94

137

117

147

425

215

276

329

355

0

0

0

Net cash used in operating activities

-21,891

-23,650

-27,533

-27,175

-31,579

-30,783

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-28,047

-

-28,683

-27,173

-21,031

-19,163

0

0

0

Purchase of property and equipment

-

-

-

-

-

-

-

-

-

39

30

24

6

3

53

66

128

127

0

0

0

Purchases of available-for-sale short-term investments

-

4,980

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of available-for-sale short-term investments

-

-

-

-

-

-

-

-

-

-

0

0

19,060

-

0

0

0

-

-

-

-

Proceeds from the maturity of available-for-sale short-term investments

-

19,000

38,000

38,000

28,000

24,000

8,000

11,000

15,500

17,705

20,170

19,061

16,786

19,582

0

0

0

-

-

-

-

Net cash provided by investing activities

-

14,020

19,074

19,074

-9,849

-8,869

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities
Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-2,280

-

4,977

-2,212

-2,362

-10,917

0

0

0

Proceeds from long-term debt

-

-

-

-

-

-

-

-

-

8,000

0

0

0

-

-

-

-

-

-

-

-

Repayment of long-term debt

0

-

-

-

-

8,320

8,320

8,320

800

8,850

0

0

0

-

-

-

-

9,930

0

0

0

Proceeds from sale of common stock and warrants, net of offering costs

-

-

-

-

-

36,456

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of common stock and warrants

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Proceeds from sale of common stock, net of offering costs

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Costs paid in connection with sales of common stock

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock under equity plans

-

-

-

-

-

-

-

-

-

172

173

173

202

178

258

300

179

179

0

0

0

Payment of tax withholdings related to net share settlements of vested restricted stock awards

6

20

20

20

20

78

78

78

78

137

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

3,940

906

-681

3

1,020

35,321

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Decrease in cash and cash equivalents

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

19,283

-

6,202

2,241

1,367

36,453

0

0

0

Increase in cash and cash equivalents

-

-

-

-

-

-

-

0

30,272

-

3,216

-8,019

-11,044

-5,663

-17,504

-27,144

-22,026

6,373

0

0

0